TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05248087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The bonded McNamara-type appliance
Description: The patient will be asked to expand twice a day until obtaining an overcorrection of 2-3 mm. Then the expander will be kept in place for three months as a retention period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The removable palatal expansion appliance
Description: The slow maxillary expansion will be applied using a removable palatal expansion appliance with a midline screw. The patient will be asked to expand twice a week until obtaining an overcorrection of 2-3 mm.
Study: NCT04186000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV vaccine
Description: The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV vaccine
Description: The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.
Study: NCT02645656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Arm
Description: Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
Study: NCT04860284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine tablets
Description: Hydroxychloroquine tablets 400mg given orally 12 hourly on day 1 and 200mg 12 hourly on day 2 to 5
Study: NCT03208062

Intervention type: OTHER
Intervention: collection of waste materials
Description: osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
Study: NCT03114020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Inhalation Solution
Description: twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
Study: NCT00853333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study: NCT03114020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhalation Solution
Description: Twice a day 3 ml of placebo inhalation solution
Study: NCT02942290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet
Study: NCT00848042

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AuroLase Therapy
Description: Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AuroLase Therapy
Description: Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AuroLase Therapy
Description: Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
Study: NCT02485821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study: NCT02540837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Obturator nerve block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Obturator nerve block with saline(placebo)
Study: NCT03765996

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decongestive Physiotherapy
Description: This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decongestive Physiotherapy plus taping
Description: This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
Study: NCT03327090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).
Description: Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).
Description: Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
Study: NCT01048463

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nutriall
Description: The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
Study: NCT04787315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional intensive functional rehabilitation + Workstations
Description: Equipment will be provided to participants where they can do exercises to increase their motor abilities at the lower limbs, trunk and upper limbs, in addition to conventional intensive functional rehabilitation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intensive functional rehabilitation
Description: Includes rehabilitation interventions provided by professionnals (OT, PT, speech language therapy, neuropsychologists...)
Study: NCT00688740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: intravenous
Study: NCT03735355

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of fibrostenotic area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TTS balloon dilation
Description: Dilation of a stricture using TTS balloon
Study: NCT00209443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadodiamide Injection
Study: NCT02673021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
Study: NCT03372616

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive left ventricular diastolic function assessment
Description: Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive aortic blood pressure measurement
Description: Aortic blood pressure will be measured with polyethylene catheter in aortic root.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-Invasive left ventricular diastolic function assessment
Description: Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
Study: NCT04094350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACF with a seed-and-recruit model
Description: The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACF with a seed-and-recruit model
Description: The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
Study: NCT04454892

Intervention type: OTHER
Intervention: Amyotrophic lateral sclerosis
Description: AMYOTROPHIC lateral sclerosis (ALS) is a degenerative disorder of motor neurons in the cortex, brainstem and spinal cord1,2. Its cause is unknown and it is uniformly fatal, typically within five years3
Study: NCT03372616

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-Invasive aortic blood pressure measurement
Description: Three devices (Sphygmocor \[AtCor Medical, Australia\], PulsePen \[DiaTecne SRL, Italy\], and Mobil-O-Graph \[IEM, Germany\] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
Study: NCT00794430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V3381
Description: 100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, bid, for 13 weeks
Study: NCT01290991

Intervention type: DEVICE
Group type: OTHER
Intervention: Augment Bone Graft
Description: Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
Study: NCT02595515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Description: Procedure: chiropractic treatment.
Study: NCT04094350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACF targeting household and neighborhood contacts
Description: In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACF targeting the older population using mobile screening units
Description: The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive case finding
Description: Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
Study: NCT02595515

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Visit without active treatment
Description: Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
Study: NCT00856557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seminar and Practicum
Description: A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
Study: NCT00120120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (CC-5013)
Description: Lenalidomide 2-5 mg capsules taken one time per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (CC-5013)
Description: Lenalidomide 2-5 mg capsules taken one time per day
Study: NCT04577170

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography
Description: Transcranial Doppler (TCD) and Transcranial Color-Coded Duplex (TCCD) ultrasonography will be performed in consecutive FD patients. All TCD and TCCD studies will be performed by stroke neurologists experienced in vascular sonography.
Study: NCT03673176

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
Study: NCT00358878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satavaptan
Description: oral administration once daily
Study: NCT00625365

Intervention type: DRUG
Group type: OTHER
Intervention: DEFINITY®
Description: DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
Study: NCT04439838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043
Study: NCT00358878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration once daily
Study: NCT04439838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043
Study: NCT02929511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciprocating single-file system
Description: The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotational single-file system.
Description: The device is moving in continuous rotational. It is a single-fie endodontic file.
Study: NCT04439838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: BI 1595043

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04716166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume-oriented incentive spirometry
Description: 3 sets of 5 repeated deep breaths using volume oriented incentive spirometry 3 times a day for 2 days
Study: NCT02929511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator Protaper multi-file system
Study: NCT00927667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drug
Description: Patients have received primary FVIII prophylaxis (started \< 2 years of age)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drug
Description: Patients have received secondary FVIII prophylaxis (started 2 - \< 6 years of age)
Study: NCT02407119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, Omeprazole or Rabeprazole, Clarithromycin
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
Study: NCT03901040

Intervention type: DEVICE
Group type: OTHER
Intervention: endoscopic ultrasound
Description: endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
Study: NCT01910155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprodex (R)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00927667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drug
Description: Patients have received secondary FVIII prophylaxis (started 6 - \< 12 years of age)
Study: NCT03295344

Intervention type: OTHER
Intervention: Diaphragm ultrasonography
Description: Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data

Intervention type: OTHER
Intervention: Tissue Doppler
Description: Determine the threshold value for diaphragm mobility
Study: NCT01502384

Intervention type: OTHER
Intervention: neurological examination
Description: motor and cognitive functions
Study: NCT00927667

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drug
Description: Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Drug
Description: Patients have received on-demand therapy
Study: NCT04059237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web based decision aid intervention
Description: Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
Study: NCT02047851

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
Study: NCT02458599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Test product
Description: Whey protein hydrolysate (20 g)
Study: NCT01447992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable artificial pancreas system with Control-To-Range
Description: We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
Study: NCT04484857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Roxadustat will be administered per dose and schedule specified in the arm description.